Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins

Nature Biotechnology
Prakash RaiRavi S Kane

Abstract

Numerous biological processes involve the recognition of a specific pattern of binding sites on a target protein or surface. Although ligands displayed by disordered scaffolds form stochastic rather than specific patterns, theoretical models predict that recognition will occur between patterns that are characterized by similar or "matched" statistics. Endowing synthetic biomimetic structures with statistical pattern matching capabilities may improve the specificity of sensors and resolution of separation processes. We demonstrate that statistical pattern matching enhances the potency of polyvalent therapeutics. We functionalized liposomes with an inhibitory peptide at different densities and observed a transition in potency at an interpeptide separation that matches the distance between ligand-binding sites on the heptameric component of anthrax toxin. Pattern-matched polyvalent liposomes inhibited anthrax toxin in vitro at concentrations four orders of magnitude lower than the corresponding monovalent peptide, and neutralized this toxin in vivo. Statistical pattern matching also enhanced the potency of polyvalent inhibitors of cholera toxin. This facile strategy should be broadly applicable to the detection and neutralization ...Continue Reading

References

Jul 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·J HolmgrenL Svennerholm
Feb 1, 1994·Protein Science : a Publication of the Protein Society·E A MerrittW G Hol
Jan 1, 1994·Progress in Lipid Research·J F TocanneA Lopez
Feb 1, 1996·Journal of Molecular Graphics·W HumphreyK Schulten
Jul 24, 1998·Biophysical Journal·S Tristram-NagleJ F Nagle
Oct 16, 1999·Proceedings of the National Academy of Sciences of the United States of America·A J GolumbfskieA K Chakraborty
Dec 15, 2000·Current Opinion in Structural Biology·E FanW G Hol
Oct 3, 2001·Nature Biotechnology·M MourezR J Collier
May 9, 2002·Proceedings of the National Academy of Sciences of the United States of America·Kristina CunninghamR John Collier
Jun 4, 2002·Nature Biotechnology·Jennifer A MaynardGeorge Georgiou
Oct 23, 2003·Annual Review of Cell and Developmental Biology·R John Collier, John A T Young
Sep 17, 2004·Nature Reviews. Microbiology·G Jonah A Rainey, John A T Young
Feb 3, 2005·Nature Reviews. Drug Discovery·Vladimir P Torchilin
Oct 4, 2005·Molecular Pharmaceutics·Kunal GujratyJeremy Mogridge

❮ Previous
Next ❯

Citations

Feb 10, 2011·Biomacromolecules·Amit JoshiRavi S Kane
Oct 13, 2012·Chemical Reviews·Ekaterina M Nestorovich, Sergey M Bezrukov
Jul 3, 2007·Journal of the American Chemical Society·Nicholas C YoderKrishna Kumar
Sep 8, 2009·Journal of the American Chemical Society·X-Y ZhuAthena Guo
Feb 6, 2010·Langmuir : the ACS Journal of Surfaces and Colloids·Ravi S Kane
Nov 21, 2007·Chemical Communications : Chem Comm·Adekunle I ElegbedeD K Srivastava
Sep 9, 2010·Proceedings of the National Academy of Sciences of the United States of America·Jin LiuRavi Radhakrishnan
Oct 10, 2007·PLoS Pathogens·Darly J ManayaniAnette Schneemann
Jun 25, 2009·The Journal of Chemical Physics·K SumithraE Straube
Aug 21, 2013·The Journal of Chemical Physics·Brian J NabloJohn J Kasianowicz
Oct 25, 2006·The Journal of Chemical Physics·K Sumithra, E Straube
Aug 30, 2006·Proceedings of the National Academy of Sciences of the United States of America·Saleem BashaRavi S Kane
Jan 23, 2014·Expert Opinion on Drug Discovery·Ekaterina M Nestorovich, Sergey M Bezrukov
Jun 9, 2007·Expert Opinion on Biological Therapy·Yan LiPeter Q Eichacker
Sep 1, 2009·Expert Opinion on Drug Discovery·Guangtao Zhang
Jun 6, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Qihang SunYouqing Shen
Jan 1, 2007·Drug Discovery Today. Disease Mechanisms·Jeremy Mogridge
Aug 30, 2008·Biotechnology and Bioengineering·David VanceRavi S Kane
Jun 26, 2009·Proceedings of the National Academy of Sciences of the United States of America·Sindhu MenonDeborah E Leckband
Sep 17, 2008·Biochemical and Biophysical Research Communications·Xuerong LiAthar H Chishti
Oct 27, 2007·Chemistry & Biology·Giuseppe DestitoMarianne Manchester
Feb 13, 2018·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Michael B DeciJuliane Nguyen
Aug 7, 2013·Journal of Nanotechnology in Engineering and Medicine·Portonovo S AyyaswamyRavi Radhakrishnan
Jul 26, 2008·Nature Nanotechnology·Amit JoshiRavi S Kane
Jun 17, 2008·Chemistry : a European Journal·Amit JoshiRavi S Kane
Sep 25, 2019·Toxins·Neža OmersaGregor Anderluh
Jan 28, 2010·Journal of Medicinal Chemistry·Dimitrios G Bouzianas
Jan 13, 2009·Macromolecules·Shuang LiuKristi L Kiick
May 28, 2009·Journal of the American Chemical Society·Sanne W A ReulenMaarten Merkx

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

© 2022 Meta ULC. All rights reserved